We are pleased to announce that daratumumab (Darzalex) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (DVRd), has been recommended for reimbursement for newly diagnosed myeloma patients undergoing a stem cell transplant, by the Canadian Drug Agency’s (CDA-AMC) pan-Canadian Oncology Drug Review Expert Review Committee. 

While patients will not be able to immediately access funding for the DVRd regimen, the recommendation remains an important step towards making additional therapeutic options for myeloma available to Canadians at earlier lines of therapy.   

Unfortunately, the Institut national d’excellence en santé et en services sociaux (INESSS) recommended that DVRd not be reimbursed in Quebec.  

Myeloma Canada remains committed to advocating for equal access to treatments like DVRd in Quebec and across the country. As such, we will continue to engage with patients, the drug manufacturer, and Quebec decision-makers.